Small Molecules

11 Nov 2019 Turning Point Therapeutics Initiates Phase 1/2 Clinical Study of TPX-0046, a Novel RET/SRC Inhibitor
11 Nov 2019 TenNor Therapeutics Reported Phase II Top-Line Results for TNP-2092
11 Nov 2019 Indalo Therapeutics Presents Phase 1 Clinical Trial Results for Lead Antifibrotic Drug Candidate IDL-2965
11 Nov 2019 Positive Data from First Clinical Study of RUC-4, a Novel Subcutaneous Platelet GPIIb/IIIa Inhibitor Designed for First Point-of-Contact STEMI Therapy, Presented at AHA 2019 Late-Breaking Science Session
11 Nov 2019 ASLAN Pharmaceuticals Announces Topline Results From TreeTopp Global Pivotal Study of Varlitinib in Biliary Tract Cancer
11 Nov 2019 Genentech’s Risdiplam Meets Primary Endpoint in Pivotal SUNFISH Trial in People With Type 2 or 3 Spinal Muscular Atrophy
09 Nov 2019 Aligos Therapeutics Presents Strong Chronic Hepatitis B Drug Candidate Portfolio at The Liver Meeting® 2019
09 Nov 2019 Gilead Announces New Data from Viral Hepatitis Research Programs at The Liver Meeting® 2019
09 Nov 2019 Gilead Presents Data on Investigational HIV-1 Capsid Inhibitor GS-6207 as a Potential Component of Long-Acting HIV Therapy
09 Nov 2019 FORMA’s FASN Inhibitor FT-4101 Significantly Reduced Hepatic De Novo Lipogenesis in Healthy Adult Subjects
08 Nov 2019 Cirius Therapeutics Announces Results from Phase 2b NASH Study Supporting Advancing to Phase 3 Development of MSDC-0602K; Data Accepted for Late Breaker Presentation at The Liver Meeting
08 Nov 2019 AbbVie Submits Supplemental New Drug Application to U.S. FDA For IMBRUVICA® (ibrutinib) in Combination with Rituximab for the Treatment of Previously Untreated, Younger Adults with Chronic Lymphocytic Leukemia
08 Nov 2019 Daiichi Sankyo Announces Positive Results from ESAX-DN Phase 3 Study in Japan of Esaxerenone in Patients with Diabetic Nephropathy
08 Nov 2019 Inflazome Progresses Two Drugs Into Clinical Trials
08 Nov 2019 Phase 3 Trial of NINLAROTM (ixazomib) as First Line Maintenance Therapy Met Primary Endpoint in Multiple Myeloma Patients not treated with Stem Cell Transplantation
08 Nov 2019 Roxadustat Significantly Increased Hemoglobin Levels for Chronic Kidney Disease Patients with Anemia in Phase III OLYMPUS and ROCKIES Trials
07 Nov 2019 Syndax Announces First Patient Dosed in Phase 1/2 AUGMENT-101 Trial of SNDX-5613 for the Treatment of Adults with Relapsed/Refractory Acute Leukemias
06 Nov 2019 Targeting RNA with Small Molecules to Drug the Undruggable: new report analyzes companies, investors, partnerships, technologies and targets from an industry perspective
06 Nov 2019 Urania Therapeutics closes a €3.5M initial seed round
06 Nov 2019 X4 Pharmaceuticals Initiates Phase 1b Clinical Trial of Mavorixafor for the Treatment of Severe Congenital Neutropenia
06 Nov 2019 eFFECTOR Therapeutics Initiates Phase 1/2 Safety and Efficacy Study of Zotatifin (eFT226) in Patients with Advanced Solid Tumor Malignancies
05 Nov 2019 EpicentRx Initiates Dosing in Phase 3 Trial of Immunotherapy RRx-001 for Third-line Small Cell Lung Cancer
05 Nov 2019 RedHill Biopharma Announces FDA Approval of Talicia® for Treatment of H. pylori in Adults
05 Nov 2019 Termination of project regarding ROR-gamma
04 Nov 2019 Revolution Medicines and Amgen Partner on Phase 1b Study to Evaluate Combination of RMC-4630 and AMG 510

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up